Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.58 |
| ▸ | CCR2 | P41597 | 17/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10222645 | 0.90 | CCR2 (0.59) | CYP2C9CCR2CYP3A4 | |
| SCHEMBL307823 | 0.90 | CYP2C9 (0.62) | CYP2C9CCR2CYP3A4KCNH2 | |
| SCHEMBL10222654 | 0.88 | CCR2 (0.52) | CYP2C9CCR2CYP3A4 | |
| SCHEMBL10223343 | 0.87 | CYP2C9 (0.59) | CYP2C9CCR2CYP3A4KCNH2 | |
| SCHEMBL306013 | 0.86 | CYP2C9 (0.58) | CYP2C9CCR2CYP3A4KCNH2 | |
| SCHEMBL306856 | 0.86 | CYP2C9 (0.58) | CYP2C9CCR2CYP3A4 | |
| SCHEMBL15449682 | 0.85 | CYP2C9 (0.64) | CYP2C9CCR2CYP3A4 | |
| SCHEMBL10223171 | 0.84 | CYP2C9 (0.63) | CYP2C9CCR2CYP3A4 | |
| SCHEMBL10223317 | 0.84 | CYP2C9 (0.54) | CYP2C9CCR2CYP3A4KCNH2 | |
| SCHEMBL10222656 | 0.83 | CCR2 (0.47) | CYP2C9CCR2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622583-B2 | Heteroaryl sulfonamides and CCR2 | CHEMOCENTRYX, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-20070037794-A1 | 4-((5-Chloro-3-(4-methyl-3-trifluoromethylbenzenesulfonylamino)pyridin-2-yl)-oxo-)1H-pyrrolo(2,3-)pyridine;interfere with ligand (monocyte chemoatactic protein-1) for chemokine receptors (CCR2); antiinflammatory agents; immunomodulators; bactericides; viricides; fungicides | CHEMOCENTRYX, INC. | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037794-A1 | 4-((5-Chloro-3-(4-methyl-3-trifluoromethylbenzenesulfonylamino)pyridin-2-yl)-oxo-)1H-pyrrolo(2,3-)pyridine;interfere with ligand (monocyte chemoatactic protein-1) for chemokine receptors (CCR2); antiinflammatory agents; immunomodulators; bactericides; viricides; fungicides | CCR2, CCR1, CCL2 | CYP2C9 1187/4885CCR2 1/4885CYP3A4 1108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.